Takeda Pharmaceutical stock holds recent gains as fundamentals improve
Published on 09/01/2026 at 22:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Takeda Pharmaceutical Company Limited (ISIN US8740602052) stock is trading near recent highs, with the New York listing around 18.00 USD as of August 31, 2026, after gaining about 15.5 percent year to date according to sector data compiled by Zonebourse.
Recent earnings show improving margins
According to financial data compiled by Zonebourse, Takeda reported operating profit (EBIT) of 408,800 million JPY for fiscal year 2026, which ended in March 2026.
This EBIT was up 19.32 percent compared with 342,600 million JPY in fiscal year 2025, indicating a clear improvement in operating profitability over the most recent year.
Over the same fiscal period, Takeda’s EBITDA margin improved to 25.08 percent from 24.10 percent a year earlier, while the EBIT margin rose from 7.48 percent to 9.07 percent, highlighting gradual margin expansion on a consolidated basis.
Revenue trends and market positioning
Segment data from Zonebourse’s segment overview show that Pharmaceutical Products revenue in fiscal year 2026 reached 4,506 billion JPY.
This compares with 4,582 billion JPY in fiscal year 2025 and 4,264 billion JPY in fiscal year 2024, meaning revenue in the core business declined by about 1.7 percent year on year after several years of growth.
Despite the slight dip in top-line, the stronger EBIT in fiscal 2026 suggests Takeda managed to improve cost efficiency and focus on higher-margin therapies within its global portfolio.
Takeda Pharmaceutical stock and key figures at a glance
Investors can find more detailed news and long-term data on Takeda Pharmaceutical stock and its latest filings in the dedicated topic overview.
Key product focus in gastrointestinal therapies
Takeda is widely known for its gastrointestinal portfolio, including the inflammatory bowel disease therapy Entyvio, which has become a major revenue contributor in recent years and underpins the company’s focus on specialty pharmaceuticals.
For retail investors, the performance of these flagship products is closely tied to Takeda’s ability to sustain the improved EBIT margin seen in fiscal year 2026, especially as competition in global pharma remains intense.
Takeda Pharmaceutical stock price context
Market data from Zonebourse’s price overview show Takeda’s New York Stock Exchange quote at 17.98 USD at the close on August 31, 2026, with the CBOE listing at 18.00 USD and a trading volume of about 32 million USD on NYSE.
The same data set indicates a year-to-date performance of plus 15.50 percent as of August 31, 2026, positioning Takeda Pharmaceutical stock among the more resilient names in the global pharmaceuticals cohort.
Takeda Pharmaceutical stock – key data
- Company: Takeda Pharmaceutical Company Limited
- ISIN: US8740602052
- Ticker: TAK
- Trading venue: NYSE
- Price (as of August 31, 2026): 17.98 USD
- Market capitalization: data as of August 27, 2026 via CompaniesMarketCap
- Sector / Industry: Pharmaceuticals / Biotechnology
- Index membership: not part of a major US blue-chip index; core listings included in Japanese benchmarks
